영문목차

This report delves into the intricacies of Medical Science Liaison (MSL) metrics within the pharmaceutical industry, providing a comprehensive analysis of both quantitative and qualitative measures used to evaluate MSL performance. It addresses the challenges and opportunities in developing meaningful metrics that align with strategic business goals and enhance stakeholder engagement. Gain insights into the impact of hybrid working models on MSL activities, the role of digital platforms in metric collection and the importance of contextualising metrics to reflect the true value of MSLs. The report also explores the potential benefits and limitations of third-party benchmarking and highlights the critical role of medical affairs teams in leading metric development and communication. This resource is essential for pharmaceutical professionals seeking to optimise MSL performance evaluation and integration into broader organisational strategies.

Key Questions Answered:

• 1. What are the current quantitative and qualitative metrics used to evaluate MSL performance?
• 2. How do MSLs perceive the effectiveness and relevance of these metrics?
• 3. What challenges do companies face in developing and implementing meaningful MSL metrics?
• 4. How has the shift to hybrid working models post-COVID-19 impacted MSL engagement metrics?
• 5. What role do MSLs play in shaping the choice and application of metrics?
• 6. How can companies ensure that MSL metrics align with broader medical affairs and business strategies?
• 7. What are the potential benefits and drawbacks of using third-party benchmarking for MSL performance?
• 8. How can qualitative metrics be developed to capture the broader impact of MSLs beyond quantitative measures?
• 9. What is the role of digital platforms in collecting and presenting MSL metrics?
• 10. How can medical affairs teams lead in the contextualisation and communication of MSL metrics within the organisation?

Key Companies:

Partial List of Participating Experts:

• An MSL at a pharmaceutical company, based in France.
• A Senior MSL at BioMarin Pharmaceutical, based in Germany.
• A Medical Science Lead at a biopharmaceutical company, based in Italy.
• A Senior MSL at a pharmaceutical company in the top 20 by global sales in 2024, based in Spain.
• MSL at GSK, based in the UK.
• Global Vice President, Medical Engagement at Teva Pharmaceuticals, based in the US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.